Transition probabilities of HER2-positive and HER2-negative breast cancer patients treated with Trastuzumab obtained from a clinical cancer registry dataset

Records of female breast cancer patients were selected from a clinical cancer registry and separated into three cohorts according to HER2-status (human epidermal growth factor receptor 2) and treatment with or without Trastuzumab (a humanized monoclonal antibody). Propensity score matching was used...

Full description

Bibliographic Details
Main Authors: Monika Pobiruchin, Sylvia Bochum, Uwe M. Martens, Meinhard Kieser, Wendelin Schramm
Format: Article
Language:English
Published: Elsevier 2016-06-01
Series:Data in Brief
Online Access:http://www.sciencedirect.com/science/article/pii/S2352340916301470